Replies to post #18595 on Ocata Therapeutics Inc fka OCAT

[Paulness]

WOW great article , Monday should be a great day for ACTC.

http://www.washingtonexaminer.com/world/ap/48690277.html

And remember this

Article (PR 3/30/09)Korea: Advacned Cell Technology and CHA BIO & amp: Diostech to Collaborate on RPE Technology Developement in Korea.

...Adavanced Cell will license its retinal pigment epithelium (RPE) technology, for the treatment of eye desease. This will be commercialized in Korea and ACTC will receive a total of $1.9 million for parties reaching certain milestones,inluding ACT making an IND submission to the FDA to commence clinical trialsin humans using the technology, which ACT currently plans to do during the second half of 2009. There was an up-front fee with the balance spread ocer 12 mo.CHA Bio will incur all of the costs associated with RPE clinical trials in Korea. One comment.